Therefore, in this work we have deeply analyzed, for the first time, the molecular mechanism of action by which a recently described natural-derived compound called T21 inhibits survivin, inducing its anticancer effects in vitro as well as in in vivo mice models, validating survivin as a promising therapeutic target for lung cancer treatment. The gene discussed is BIRC5; the disease is lung carcinoma.